| Name | PCO371 |
|---|---|
| Synonyms |
1-{3,5-Dimethyl-4-[2-({4-oxo-2-[4-(trifluoromethoxy)phenyl]-1,3,8-triazaspiro[4.5]dec-1-en-8-yl}sulfonyl)ethyl]phenyl}-5,5-dimethyl-2,4-imidazolidinedione
2,4-Imidazolidinedione, 1-[3,5-dimethyl-4-[2-[[4-oxo-2-[4-(trifluoromethoxy)phenyl]-1,3,8-triazaspiro[4.5]dec-1-en-8-yl]sulfonyl]ethyl]phenyl]-5,5-dimethyl- |
| Description | PCO371 is an orally active full agonist of parathyroid hormone receptor 1 (PTHR1), with no effect on PTH type 2 receptor. |
|---|---|
| Related Catalog | |
| Target |
PTHR1[1] |
| In Vitro | PCO371 is an orally active full agonist of parathyroid hormone receptor 1 (PTHR1), with no effect on PTH type 2 receptor. PCO371 induces cAMP production with an EC50 of 2.4 μM in COS-7 cells expressing hPTHR1, and 2.5 μM in COS-7 cells transfected with hPTHR1-delNT, and also enhances the phospholipase C activity (EC50, 17 μM)[1]. |
| References |
| Density | 1.5±0.1 g/cm3 |
|---|---|
| Molecular Formula | C29H32F3N5O6S |
| Molecular Weight | 635.654 |
| Exact Mass | 635.202515 |
| LogP | 4.56 |
| Index of Refraction | 1.636 |
| Storage condition | 2-8°C |